KRAS mutation-driven enhanced macropinocytosis: using albumin as a trojan horse for delivering nanomedicine.

Abstract

Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS), the most mutated oncogene, drives tumoral progression by leveraging macropinocytosis. This nutrient uptake pathway is responsible for promoting the relentless growth of KRAS-mutant tumoral cells while also unlocking a new frontier for the exploration of innovative therapeutic approaches. Leveraging KRAS-driven macropinocytosis, researchers are instigating advanced nanoparticulate drug delivery systems, including albumin nanoparticles and DNA- and RNA-loaded lipid nanoparticles. We emphasize the emerging strategies to exploit KRAS-macropinocytosis-albumin crosstalk presenting a promising avenue for the delivery of albumin nanoparticles in cancer therapy.